Technical Insights on Drug-Coated Balloons II

  • Manish Doshi
  • Prakash SojitraEmail author
  • Dinesh Shah
  • Sameer Dani
  • Alexandre Abizaid


The drug-coated balloon is a future treatment device which leaves nothing behind. It delivers the drug in a very short time and provides long-term release of the drug to treat posttreatment shortcomings. Currently paclitaxel and sirolimus are the only choices for drug-coated balloons. Preclinical study findings on paclitaxel are mixed and depend on various factors such as the drug carrier, balloon surface, drug size, coating method etc. The sirolimus-coated balloon is an emerging device and based on certain preclinical reports, it has generated new hope for safe and effective drug delivery.


Sirolimus-coated balloon Sirolimus Excipient 


  1. 1.
    Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99. Scholar
  2. 2.
    Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–65. Scholar
  3. 3.
    Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR, IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502. Scholar
  4. 4.
    Cortese B, Granada JF, Scheller B, Schneider PA, Tepe G, Scheinert D, Garcia L, Stabile E, Alfonso F, Ansel G, Zeller T. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J. 2016;37(14):1096–103. Scholar
  5. 5.
    Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel coated balloon catheter. N Engl J Med. 2006;355:2113–24. Scholar
  6. 6.
    Scheller B, Clever YP, Kelsch B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Speck U, Böhm M, Cremers B. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012;5:323–30. Scholar
  7. 7.
    Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119:2986–94. Scholar
  8. 8.
    Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Breithardt OA, Schmidt M, Zimmermann S, Lonke S, von Cranach M, Nguyen TV, Daniel WG, Wöhrle J. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012;59:1377–82. Scholar
  9. 9.
    Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, Katoh H, Oka N, Fuku Y, Hosogi S, Hirono A, Maruo T, Tanaka H, Shigemoto Y, Hasegawa D, Tasaka H, Kusunose M, Otsuru S, Okamoto Y, Saito N, Tsujimoto Y, Eguchi H, Miyake K, Yoshino M. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4:149–54. Scholar
  10. 10.
    Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, Schulz S, Fusaro M, Ott I, Ibrahim T, Hausleiter J, Valina C, Pache J, Laugwitz KL, Massberg S, Kastrati A, ISAR-DESIRE 3 investigators. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381:461–7. Scholar
  11. 11.
    Liistro F, Porto I, Angioli P, Grotti S, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G, Bolognese L. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–21. Scholar
  12. 12.
    Speck U, Cremers B, Kelsch B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, Hanisch U, Böhm M, Scheller B. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv. 2012;5:392–400. Scholar
  13. 13.
    Granada JF, Tellez A, Baumbach WR, Bingham B, Keng YF, Wessler J, Conditt G, McGregor J, Stone G, Kaluza GL, Leon MB. In vivo delivery and long-term tissue retention of nano-encapsulated sirolimus using a novel porous balloon angioplasty system. EuroIntervention. 2016;12(6):740–7. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cremers B, Toner JL, Schwartz LB, von Oepen R, Speck U, Kaufels N, Clever YP, Mahnkopf D, Böhm M, Scheller B. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol. 2012;101:469–76. Scholar
  15. 15.
    Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617–24. Scholar
  16. 16.
    Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852–5.CrossRefGoogle Scholar
  17. 17.
    Birkmeier KA, Kastrati A, Byrne RA, Holle H, Schulz S, Tiroch K, et al. Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. Catheter Cardiovasc Interv. 2011;77:494–501.CrossRefGoogle Scholar
  18. 18.
    Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol. 2012;161:4–12.CrossRefGoogle Scholar
  19. 19.
    Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug eluting stent in porcine coronary arteries. Radiology. 2006;240:411–8.CrossRefGoogle Scholar
  20. 20.
    Albrecht T, Speck U, Baier C, et al. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol. 2007;42:579–85.CrossRefGoogle Scholar
  21. 21.
    Posa A, Nyolczas N, Hemetsberger R, Pavo N, Petnehazy O, Petrasi Z, et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv. 2010;76(3):395–403.CrossRefGoogle Scholar
  22. 22.
    Belkacemi A, Agostoni P, Voskuil M, Doevendans P, Stella P. Drug-eluting balloons in coronary artery disease — current and future perspectives. Eur Cardiol. 2012;8:56–9.CrossRefGoogle Scholar
  23. 23.
    Xiong GM, Ang H, Lin J, Lui YS, Phua JL, Chan JN, et al. Materials technology in drug eluting balloons: current and future perspectives. J Control Release. 2016;239:92–106.CrossRefGoogle Scholar
  24. 24.
    Peterson S, Hasenbank M, Silvestro C, Raina S. IN.PACT™ Admiral™ drug-coated balloon: durable, consistent and safe treatment for femoropopliteal peripheral artery disease. Adv Drug Deliv Rev. 2016;112:69–77.CrossRefGoogle Scholar
  25. 25.
    Micari A, Cioppa A, Vadala G, Stabile E, Castriota F, Pantaleo P, et al. A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results. EuroIntervention. 2011;7(Suppl K):K77–82.CrossRefGoogle Scholar
  26. 26.
    Radke P, Joner M, Joost A, Byrne R, Hartwig S, Bayer G, Steigerwald K, Wittchow E. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipient. EuroIntervention. 2011;7(6):730–7.CrossRefGoogle Scholar
  27. 27.
    Cheng Y, Shibuya M, McGregor J, Conditt G, Yi G-H, Kaluza G, Gray W, Doshi M, Sojitra P, Granada J. Biological effect on restenosis and vascular healing of encapsulated paclitaxel nanocrystals delivered via coated balloon technology in the familial hypercholesterolaemic swine model of in-stent restenosis. EuroIntervention. 2016;12(9):1164–73.CrossRefGoogle Scholar
  28. 28.
    Lemos Neto PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, et al. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013;9(1):146–56. Scholar
  29. 29.
    Takimura CK, Galon MZ, Sojitra P, Doshi M, Aiello V, Gutierrez PS, Carvalho J, Ferreira SK, Chaves MJF, Laurindo FRM, Lemos PA. Excipient:drug dose determination for neointimal hyperplasia as assessed by optical coherence tomography and histopathology in porcine coronary arteries after sirolimus-eluting balloon deployment. Rev Bras Cardiol Invasiva. 2012;20(2):133–9.Google Scholar
  30. 30.
    Slagboom T, Amoroso G, Jensen LO, Granada JF, Stella P. The SABRE trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): angiographic results and 1-year clinical outcomes. JACC Cardiovasc Interv. 2017;10(20):2029–37.CrossRefGoogle Scholar
  31. 31.
    Bersin RM. Update on sirolimus coated balloon technologies. In: Cardiovascular Research Technologies (CRT 17), Washington, DC, 18–21 Feb 2017.Google Scholar
  32. 32.
    Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol. 2006;58(5):665–72.CrossRefGoogle Scholar
  33. 33.
    Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810–4.CrossRefGoogle Scholar
  34. 34.
    Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004–14. Scholar
  35. 35.
    Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A. 2004;101:9463–7. Scholar
  36. 36.
    Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Recio M, Masotti M, Velázquez MT, Sanchís J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C, RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63:1378–86. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Manish Doshi
    • 1
  • Prakash Sojitra
    • 1
    Email author
  • Dinesh Shah
    • 2
  • Sameer Dani
    • 3
  • Alexandre Abizaid
    • 4
  1. 1.Concept Medical Research Private LimitedSuratIndia
  2. 2.William Beaumont HospitalRoyal OakUSA
  3. 3.Apollo HospitalsAhmedabadIndia
  4. 4.Instituto Dante Pazzanese de CardiologiaSao PauloBrazil

Personalised recommendations